Adjuvant PD-1 AntibodyTislelizumab in Combination With Capecitabine for Patients With Cholangiocarcinoma at High-Risk of Postoperative Recurrence
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Tislelizumab (Primary) ; Capecitabine
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 09 Mar 2021 New trial record